How Have High Cost Hepatitis C Drugs Impacted Specialty Pharmacy?

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

Related Content:

InterviewsHepatitisSpecialty Pharmacy
Establishing Workflow for In-clinic, Home Administration of Cabotegravir-rilpivirine Injections for HIV-1
Data Points Show Value in Oncology Pharmacy
Updates in Prevention, Treatment of Cytokine Release Syndrome, Neurologic Toxicities for Patients With Multiple Myeloma